- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
ENDP Market Currents
more »
-
May 17 Buckingham says Watson Pharmaceuticals (WPI -1.3%) remains a Top Pick , given its attractive growth profile, Actavis acquisition benefits and continued settlement discussions with Endo (ENDP -0.8%). The firm reiterates its Buy rating with a $100 price target.
Comment![Healthcare]
ENDP in Focus
more »
ENDP Related Articles
more »
ENDP News
more »
-
at MarketWatch.com (Feb 24, 2012)
-
at MarketWatch.com (Feb 23, 2012)
-
at MarketWatch.com (Dec 12, 2011)
-
at CNBC.com (Nov 18, 2011)
-
at MarketWatch.com (Jun 28, 2011)
ENDP Press Releases and Filings
more »
-
PR Newswire (Wed, 2:00PM)
-
PR Newswire (May 4, 2012)
-
PR Newswire (Apr 17, 2012)
-
PR Newswire (Mar 13, 2012)
-
PR Newswire (Mar 1, 2012)
ENDP Latest Transcript
more »
ENDP Cramer
more »
-
Tue, Oct 19, 2010
-
Fri, Jan 9, 2009
ENDP Instablog posts
more »
ENDP vs. ETF Alternatives
Company Description
We are a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of branded and generic prescription pharmaceuticals used primarily to treat and manage pain, overactive bladder, prostate and bladder cancer, and the early onset of puberty in... More